Opioid Metabolism

Overview

Journal Mayo Clin Proc

Specialty General Medicine

Date 2009 Jul 2

PMID 19567715

Citations 206

Authors

Howard S Smith

Affiliations

Soon will be listed here.

Abstract

Clinicians understand that individual patients differ in their response to specific opioid analgesics and that patients may require trials of several opioids before finding an agent that provides effective analgesia with acceptable tolerability. Reasons for this variability include factors that are not clearly understood, such as allelic variants that dictate the complement of opioid receptors and subtle differences in the receptor-binding profiles of opioids. However, altered opioid metabolism may also influence response in terms of efficacy and tolerability, and several factors contributing to this metabolic variability have been identified. For example, the risk of drug interactions with an opioid is determined largely by which enzyme systems metabolize the opioid. The rate and pathways of opioid metabolism may also be influenced by genetic factors, race, and medical conditions (most notably liver or kidney disease). This review describes the basics of opioid metabolism as well as the factors influencing it and provides recommendations for addressing metabolic issues that may compromise effective pain management. Articles cited in this review were identified via a search of MEDLINE, EMBASE, and PubMed. Articles selected for inclusion discussed general physiologic aspects of opioid metabolism, metabolic characteristics of specific opioids, patient-specific factors influencing drug metabolism, drug interactions, and adverse events.

Citing Articles

Risk of hospital inpatient opioid overdose (RHINOO): a review of factors impacting naloxone administration in patients receiving opioids.

Alban H, Ireifej N, DAlessandro J, Jordan G, Lee R, Patricia N Eur J Clin Pharmacol. 2025; .

PMID: 39849175 DOI: 10.1007/s00228-025-03801-1.

Lower Diversity of Amylase-Trypsin Inhibitors and -Released Opioid-Containing Peptides in Ancestral Compared to Modern Wheat Varieties Assessed by Proteomics and Peptidomics.

Asledottir T, Mamone G, Picariello G, Vegarud G, Roseth A, Ferranti P J Agric Food Chem. 2025; 73(4):2373-2380.

PMID: 39813239 PMC: 11783586. DOI: 10.1021/acs.jafc.4c05959.

Catalyzing Pharmacogenomic Analysis for Informing Pain Treatment (C-PAIN): A Randomized Trial of Preemptive Genotyping in Cancer Palliative Care.

Cho Y, Karrison T, Jack M, Choksi A, Knoebel R, Yeo K J Pain Res. 2024; 17:4187-4196.

PMID: 39717756 PMC: 11664000. DOI: 10.2147/JPR.S488416.

Could chronic opioid use be an additional risk of hepatic damage in patients with previous liver diseases, and what is the role of microbiome?.

Tarantino G, Cataldi M, Citro V Front Microbiol. 2024; 15:1319897.

PMID: 39687876 PMC: 11646994. DOI: 10.3389/fmicb.2024.1319897.

Opioid use and poisoning in hospitalized patients with chronic kidney disease.

Zaidan N, Jalloul Y, Goldfarb D, Azar H, El-Sayegh S J Nephrol. 2024; .

PMID: 39616593 DOI: 10.1007/s40620-024-02159-4.

References

Totah R, Allen K, Sheffels P, Whittington D, Kharasch E . Enantiomeric metabolic interactions and stereoselective human methadone metabolism. J Pharmacol Exp Ther. 2007; 321(1):389-99. DOI: 10.1124/jpet.106.117580. View

Gasche Y, Daali Y, Fathi M, Chiappe A, Cottini S, Dayer P . Codeine intoxication associated with ultrarapid CYP2D6 metabolism. N Engl J Med. 2004; 351(27):2827-31. DOI: 10.1056/NEJMoa041888. View

Aklillu E, Persson I, Bertilsson L, Johansson I, Rodrigues F, Ingelman-Sundberg M . Frequent distribution of ultrarapid metabolizers of debrisoquine in an ethiopian population carrying duplicated and multiduplicated functional CYP2D6 alleles. J Pharmacol Exp Ther. 1996; 278(1):441-6. View

Halling J, Weihe P, Brosen K . CYP2D6 polymorphism in relation to tramadol metabolism: a study of faroese patients. Ther Drug Monit. 2008; 30(3):271-5. DOI: 10.1097/FTD.0b013e3181666b2f. View

Inturrisi C . Pharmacology of methadone and its isomers. Minerva Anestesiol. 2005; 71(7-8):435-7. View

Wallace M, Magnuson S . Opioid substitution to improve the effectiveness of chronic noncancer pain control: a chart review. Anesth Analg. 2000; 90(4):933-7. DOI: 10.1097/00000539-200004000-00029. View

. Practice guidelines for acute pain management in the perioperative setting: an updated report by the American Society of Anesthesiologists Task Force on Acute Pain Management. Anesthesiology. 2004; 100(6):1573-81. DOI: 10.1097/00000542-200406000-00033. View

Relling M, Cherrie J, Schell M, Petros W, Meyer W, Evans W . Lower prevalence of the debrisoquin oxidative poor metabolizer phenotype in American black versus white subjects. Clin Pharmacol Ther. 1991; 50(3):308-13. DOI: 10.1038/clpt.1991.141. View

Reisfield G, Salazar E, Bertholf R . Rational use and interpretation of urine drug testing in chronic opioid therapy. Ann Clin Lab Sci. 2007; 37(4):301-14. View

10.

George S, Braithwaite R . A pilot study to determine the usefulness of the urinary excretion of methadone and its primary metabolite (EDDP) as potential markers of compliance in methadone detoxification programs. J Anal Toxicol. 1999; 23(2):81-5. DOI: 10.1093/jat/23.2.81. View

11.

Haberer J, Schoeffler P, Couderc E, Duvaldestin P . Fentanyl pharmacokinetics in anaesthetized patients with cirrhosis. Br J Anaesth. 1982; 54(12):1267-70. DOI: 10.1093/bja/54.12.1267. View

12.

Kirchheiner J, Schmidt H, Tzvetkov M, Keulen J, Lotsch J, Roots I . Pharmacokinetics of codeine and its metabolite morphine in ultra-rapid metabolizers due to CYP2D6 duplication. Pharmacogenomics J. 2006; 7(4):257-65. DOI: 10.1038/sj.tpj.6500406. View

13.

Bush E, Miller C, Friedman I . A case of serotonin syndrome and mutism associated with methadone. J Palliat Med. 2006; 9(6):1257-9. DOI: 10.1089/jpm.2006.9.1257. View

14.

Klepstad P, Borchgrevink P, Dale O, Zahlsen K, Aamo T, Fayers P . Routine drug monitoring of serum concentrations of morphine, morphine-3-glucuronide and morphine-6-glucuronide do not predict clinical observations in cancer patients. Palliat Med. 2003; 17(8):679-87. DOI: 10.1191/0269216303pm835oa. View

15.

Lalovic B, Kharasch E, Hoffer C, Risler L, Liu-Chen L, Shen D . Pharmacokinetics and pharmacodynamics of oral oxycodone in healthy human subjects: role of circulating active metabolites. Clin Pharmacol Ther. 2006; 79(5):461-79. DOI: 10.1016/j.clpt.2006.01.009. View

16.

Duguay Y, Baar C, Skorpen F, Guillemette C . A novel functional polymorphism in the uridine diphosphate-glucuronosyltransferase 2B7 promoter with significant impact on promoter activity. Clin Pharmacol Ther. 2004; 75(3):223-33. DOI: 10.1016/j.clpt.2003.10.006. View

17.

Cone E, Welch P, Paul B, Mitchell J . Forensic drug testing for opiates, III. Urinary excretion rates of morphine and codeine following codeine administration. J Anal Toxicol. 1991; 15(4):161-6. DOI: 10.1093/jat/15.4.161. View

18.

Li Y, Kantelip J, Gerritsen-van Schieveen P, Davani S . Interindividual variability of methadone response: impact of genetic polymorphism. Mol Diagn Ther. 2008; 12(2):109-24. DOI: 10.1007/BF03256276. View

19.

Mbanefo C, Bababunmi E, Mahgoub A, Sloan T, Idle J, Smith R . A study of the debrisoquine hydroxylation polymorphism in a Nigerian population. Xenobiotica. 1980; 10(11):811-8. DOI: 10.3109/00498258009033811. View

20.

Evans D, Mahgoub A, Sloan T, Idle J, Smith R . A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population. J Med Genet. 1980; 17(2):102-5. PMC: 1048511. DOI: 10.1136/jmg.17.2.102. View